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Using VAAST to Identify an X-Linked Disorder
Resulting in Lethality in Male Infants
Due to N-Terminal Acetyltransferase Deficiency
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John M. Opitz,1,4,6,10,11 Cathy A. Stevens,12 Tao Jiang,13,14 Christa Schank,8 Heidi Deborah Fain,15
Reid Robison,15 Brian Dalley,16 Steven Chin,6 Sarah T. South,1,7 Theodore J. Pysher,6 Lynn B. Jorde,4
Hakon Hakonarson,2 Johan R. Lillehaug,3 Leslie G. Biesecker,5 Mark Yandell,4 Thomas Arnesen,3,17
and Gholson J. Lyon15,18,20,*
We have identified two families with a previously undescribed lethal X-linked disorder of infancy; the disorder comprises a distinct
combination of an aged appearance, craniofacial anomalies, hypotonia, global developmental delays, cryptorchidism, and cardiac
arrhythmias. Using X chromosome exon sequencing and a recently developed probabilistic algorithm aimed at discovering disease-
causing variants, we identified in one family a c.109T>C (p.Ser37Pro) variant in NAA10, a gene encoding the catalytic subunit of the
major human N-terminal acetyltransferase (NAT). A parallel effort on a second unrelated family converged on the same variant. The
absence of this variant in controls, the amino acid conservation of this region of the protein, the predicted disruptive change, and
the co-occurrence in two unrelated families with the same rare disorder suggest that this is the pathogenic mutation. We confirmed
this by demonstrating a significantly impaired biochemical activity of the mutant hNaa10p, and from this we conclude that a reduction
in acetylation by hNaa10p causes this disease. Here we provide evidence of a human genetic disorder resulting from direct impairment of
N-terminal acetylation, one of the most common protein modifications in humans.Introduction
Researchers have used exon capture and high-throughput
sequencing (exome sequencing) to identify the molecular
etiology of several Mendelian disorders.1–5 It has been
used in studies of a multigenerational pedigree6 and a de
novo disorder,1 and it has been applied in molecular diag-
nostics.7 Most of these efforts have focused on character-
izing previously described and recognizable genetic
syndromes, such as Kabuki (MIM 147920),1 Miller (MIM
263750),2,8 and TARP (MIM 311900)9 syndromes. These
efforts to search for the molecular etiology of known
syndromes benefited from years of clinical evaluations,
allowing researchers to combine unrelated individuals in
the same cohort for analysis.
In contrast, exon capture and sequencing can help to
identify previously unrecognized syndromes. We have
characterized such a syndrome, in which the afflicted
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and cardiac arrhythmias. To determine the genetic basis
of this syndrome, we used X chromosome exon capture
and sequencing and a recently developed probabilistic
algorithm aimed at discovering disease-causing variants.
We also demonstrate that this phenotype results from
a decrease in the function of an enzyme involved in
N-terminal acetylation of proteins.Subjects and Methods
We describe two parallel genetic research efforts that converged on
the same gene variant. The two groups working on this project
became aware of each other’s work after the genetic analyses had
beencompleted, andtherefore themethodologiesusedvaried some-
what. When these methods differed, they are described separately.
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respectively. Written informed consent was obtained from the
parents of affected children for collected blood samples and ex-
tracting DNA from stored samples. Blood samples were collected
and genomic DNA extracted with alkaline lysis and ethanol
precipitation (Gentra Puregene, QIAGEN, USA). TwoDNA samples
from family 1 were extracted from stored formalin-fixed-paraffin-
embedded (FFPE) tissues from the prior autopsies of two of the
deceased boys. Slices from FFPE tissue blocks were digested over-
night in proteinase K and then boiled for 10 min to inactivate
the enzyme. The crude lysates were diluted 1:10 for PCR.Genomic Microarrays and Copy-Number
Variation Analysis
Copy-number variation in individual III-4 in family 1 was evalu-
ated with two oligonucleotide-based genomic microarray
platforms, the U-array Cyto6000 (manufactured by Agilent Tech-
nologies, Santa Clara, CA) and the SignatureChip Oligo Solution
microarray (manufactured by Roche NimbleGen). Both platforms
use a custom design with approximately 10 kb coverage for many
clinically relevant syndromes and telomere and pericentromeric
regions,; the genome-wide coverage is 75 kb for the U-array and
35 kb for the SignatureChipOS. The U-array data were analyzed
with DNA Analytics 4.0.76 software from Agilent Technologies
with the ADM-1 algorithm. The SignatureChipOS data
were analyzed with Genoglyphix software (Signature Genomics,
Spokane, WA).X-Chromosome Exon Capture and Sequencing
Exon capture for family 1 was carried out with a commercially
available Agilent in-solution method (SureSelect Human X chro-
mosome kit, Agilent) as per the manufacturer guidelines with
minor modifications. Randomly fragmenting the pure and high-
molecular-weight genomic DNA samples with a Covaris S series
Adaptive Focused Acoustics machine resulted in DNA fragments
with a base pair peak of 150 to 200 bps. Adaptors were then ligated
to both ends of the resulting fragments. The adaptor-ligated
templates were purified by the Agencourt AMPure SPRI beads.
Adaptor-ligated products were amplified by PCR with Phusion
polymerase (six cycles) and subsequently purified with a QIAGEN
QIAquick PCR purification kit. The quality and size distribution of
the amplified product was assessed on an Agilent Bioanalyzer DNA
1000 chip. Amplified library (500 ng) with a size range of 200–
400 bp was hybridized to SureSelect Biotinylated RNA Library
(BAITS) for enrichment. Hybridized fragments were bound to
the strepavidin beads whereas nonhybridized fragments were
washed out after a 24 hr hybridization. The captured library was
enriched by amplification by PCR (12 cycles), and the amplified
product was subsequently qualified on an Agilent High Sensitivity
DNA Bioanalyzer chip to verify the size range and quantity of the
enriched library. Each captured library was sequenced with
76 bp single-end reads on one lane each of the Illumina GAIIx
platform. Raw image files were processed by Illumina Pipeline
v1.6 for base-calling with default parameters. All coordinates are
based on the human genome build hg18. The pseudoautosomal
regions were defined based on annotations within the
UCSC genome browser. Specifically, these are the regions
chrX:1–2709520, chrX:154584238–154913754, chrY:1–2709520,
and chrY:57443438-57772954. For family 2, solution hybridiza-
tion selection of the X exome (Sure Select, Agilent, Santa Clara,
CA) was used to produce a paired-end sequencing library
(Illumina, San Diego, CA) as previously described.9 Paired-endThe75 bp reads were generated from the target-selected DNA library
in one lane of an Illumina GAIIx. Coding changes were predicted
with custom-designed software.9Sanger Sequence-Confirmation Analysis
Amplification by PCR and Sanger sequencing were performed as
described so that mutations and the cosegregation could be
confirmed.10 Mutation numbering was performed according to
Human Gene Variation Society nomenclature with reference
NM_003491.2.Sequence Alignment
For family 1, sequence reads were converted from Illumina fastq
format to fastq files that conform to the Sanger specification for
base-quality encoding with perl scripts. Burroughs Wheeler align-
ment (BWA)11 version 0.5.8 was used to align the sequencing
reads, and the default parameters were used for fragment reads,
to the human genome sequence build 36 downloaded from the
UCSC Genome Browser or the 1000 Genomes Project websites.12
Alignments were converted from SAM format to sorted, indexed
BAM files with SamTools.13 The picard tool was used to remove
invalid alignments and remove duplicate reads from the BAMfiles.
Regions surrounding potential indels were realigned with the
GATK IndelRealigner tool.14 Variants were called with SamTools
pileup commandwith the default parameters except that no upper
limit was placed on the depth of coverage for calling variants. In
addition, haploid chromosomes were called with the -N 1 options
SamTools pileup. Variants were annotated with respect to their
impact on coding features with perl scripts and the knownGenes
and RefGenes tracks from the UCSC Genome Browser.15
Genotype Calling
Regions surrounding potential indels were realigned with the
GATK IndelRealigner tool.14 Genotypes were called with both
SamTools (pileup command) and the GATK UnifiedGenotypeCal-
ler and IndelCaller.14 We then analyzed the union of single nucle-
otide variant (SNV) and indel variant calls from GATK and Sam-
Tools with the ANNOVAR program16 to identify exonic variants
and to identify variants not previously reported in the 1000
Genomes Project and the dbSNP version 130. All variant calls
not present on the X chromosome were removed given the
X-linked nature of the disease.We analyzed the location and geno-
type of variants for each individual to locate the subset of variants
on the X chromosome that were heterozygous in female carriers,
hemizygous in individual III-4, and a hemizygous reference in
the unaffected males. Each candidate variant was also screened
for presence or absence in dbSNP 130,17 the 10Gen Dataset18
and variant data from the 1000 Genomes Project.12
We also used the read-mapping and SNV-calling
algorithmGNUMAP19 independently to align the reads from the
Illumina.qseq files to the X chromosome (human sequence
build 36) and to simultaneously call SNVs. GNUMAP utilizes
a probabilistic pair-hiddenMarkovmodel (PHMM) for base calling
and SNV detection that incorporates base uncertainty on the basis
of the quality scores from the sequencing run, as well as mapping
uncertainty from multiple optimal and suboptimal alignments of
the read to a given location to the genome. In addition, this
approach applies a likelihood ratio test that provides researchers
with straightforward SNV-calling cutoffs based on a p value cutoff
or a false discovery control. Reads were aligned and SNVs called for
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uncle weremade assuming a haploid genome (because the calls are
on the X chromosome), whereas heterozygous calls were allowed
for the mother and grandmother. SNVs were selected based on
a p value cutoff of 0.001. Because of the X-linked nature of the
disease, candidate SNVs were selected that are heterozygous in
the mother and grandmother and different between the uncle
and brother and individual III-4.
Variant Annotation, Analysis,
and Selection Tool Analysis
The SNV filtering was performed with the simple selection tool
(SST) module in variant annotation, analysis, and selection tool
(VAAST) on the basis of on the SNV position. Our analysis applied
a disease model that did not require complete penetrance or locus
homogeneity. We restricted the expected allele frequency of puta-
tive disease-causing variants within the control genomes to 0.1%
or lower. The background file used in the analysis is composed
of variants from dbSNP (version 130), 189 genomes from the
1000 Genomes Project,12 the 10Gen dataset,18 184 Danish
exomes,20 and 40 whole genomes from the Complete Genomics
Diversity Panel. VAAST candidate-gene prioritization analysis
was performed with the likelihood ratio test under the domi-
nant-inheritance model. An expected allele frequency of 0.1% or
lower was assumed for the causal variant in the general popula-
tion. After masking out loci of potentially low variant quality,
SNVs in each gene were scored as a group. The significance
level was assessed with individual permutation tests (the
following VAAST analysis parameters were used ‘‘-m lrt -c X -g 4
-d 1.E8 -r 0.001 -x 35bp_se.wig -less_ram -inheritance d’’).
Short-Tandem-Repeat Genotyping
Genotyping on family 1 was performed on DNA extracted from
peripheral blood or FFPE tissues with a panel of 16 polymorphic
short-tandem-repeat (STR) genotyping markers spanning the
long arm of chromosome X (Applied Biosystems LinkageMapping
Set v2.5- MD10 and custom primers DXS8020, DXS1275,
DXS6799, DXS1203, DXS8076, and DXS8037). Fluorescently
labeled PCR products were separated with an Applied Biosystems
3130XL Genetic Analyzer and analyzed with GeneMapper Soft-
ware version 3.7. Genotyping and haplotype analysis for family
2 was performed for a subset of markers on the X chromosome
(DXS9900, DXS9896, DXS8016, DXS1003, DXS2132, DXS990,
DXS6797, DXS8057, GATA31E08, DXS7127, and DXS1073) as
described.21
Analysis of Haplotype Sharing
Using GNUMAP software and the X chromosome exon sequence
data from family 1, we derived 1322 polymorphic markers on
the mother’s X chromosomes. We then determined the regions
shared or not shared by individual III-4 and his unaffected brother.
Screening for Frequency of Causal Variants
Wemanually screened for the presence or absence of c.109T>C in
NAA10 in dbSNP (version 130), 401 participants in the ClinSeq
project,22 180 genomes from the 1000 Genomes Project,12 the
10Gen dataset,18 184 Danish exomes,20 and 40 whole genomes
from the Complete Genomics Diversity Panel.
Sorting Intolerant From Tolerant Analysis
The sorting intolerant from tolerant (SIFT) sequence was usedwith
the sequence of hNaa10p (NP_003482) as input. The following30 The American Journal of Human Genetics 89, 28–43, July 15, 2011parameters were used: the database searched was the UniProt-Swis-
sProt þ TrEMBL 2010_09 and the median conservation of
sequences was 3.00 (between 0 and 4.32, between 2.75 and 3.25
is recommended). The substitution at position 37 from S to P
was predicted to affect protein function with a score of 0.00. The
median sequence conservation was 3.02; 119 sequences were
represented at this position. The threshold for intolerance is
0.05 (less is predicted not tolerated).Plasmid Construction, Mutagenesis,
Protein Production, Purification,
and In Vitro Acetyltransferase Assays
The cDNA encoding hNaa10p WT was cloned into the pETM-41
vector (Maltose Binding Protein [MBP]/His-fusion) (from G. Stier,
EMBL, Heidelberg, Germany) for expression in Escherichia coli.
The plasmid encoding hNaa10p p.Ser37Pro was made by
site-directed mutagenesis with the primers hNAA10 T109C F: 50-C
TTCTACCATGGCCTTCCCTGGCCCCAGCTC-30 and hNAA10
T109C R: 50-GAGCTGGGGCCAGGGAAGGCCATGGTAGAAG-30
according to the instruction manual (QuikChange Site-Directed
Mutagenesis Kit, Stratagene). Correct cloning and mutagenesis
were verified by DNA sequencing and the plasmids were trans-
formed into E. coli BL21 Star (DE3) cells (Invitrogen) by heat shock.
The 200 ml cell cultures were grown in Luria Bertani (LB) medium
to an OD600 nm of 0.6 at 37
C and subsequently transferred to
20C. After 30 min of incubation, protein production was induced
by adding IPTG to a final concentration of 0.5 mM. After 17 hr of
incubation, the cells were harvested by centrifugation, and the
bacterial pellets were stored at 20C. E. coli pellets containing
recombinant proteins were thawed at 4C and lysed by sonication
and French press in lysis buffer (1 mM DTT, 50 mM Tris-HCl
[pH 7.4], 300 mM NaCl, and one tablet EDTA-free protease Inhib-
itor cocktail [Roche] per 50 ml). The cell extracts were applied on
a metal affinity fast protein liquid chromatography column
(HisTrap HP, GE Healthcare, Sweden). Fractions containing
recombinant protein were pooled and subjected to size-exclusion
chromatography (Superdex 75 16/60, GE Healthcare). Fractions
containing the monomeric recombinant protein were pooled,
and the protein purity was analyzed by SDS-PAGE gel electro-
phoresis. The protein concentrations were determined by
OD280 nm measurements.
In the assays investigating the N-terminal acetyltransferase
activity toward selected substrate peptides, purifiedMBP-hNaa10p
WT or p.Ser37Pro were mixed with oligopeptides, acetyl-CoA and
acetylation buffer. After incubation at 37C, the acetylation reac-
tion products were quantified with RP-HPLC as described previ-
ously.11,13 In the assays investigating the N-terminal acetyltrans-
ferase activity toward the acidic N termini of actins (DDDIA or
EEEIA), 15 nM of purified MBP-hNaa10p WT or S37P were mixed
with 250 mM of oligopeptides. In the assays where the AVFAD and
SESSS based oligopeptides were tested, 250 nM of purified enzyme
were mixed with 200 mM of mentioned oligopeptides. All samples
were furthermixedwith 400 mMacetyl-CoA and acetylation buffer
(1 mM DTT, 50 mM Tris-HCl [pH 8.5], 800 uM EDTA, 10% glyc-
erol) in a total volume of 100 ml. The samples with actin-based oli-
gopeptides as substrates were incubated at 37C for 15 min,
whereas the SESSS and AVFAD reactions were incubated at 37C
for 20 min. In the time-course acetylation experiments, the
same conditions as mentioned above were used, and samples
were collected at indicated times. For all aliquots collected, the
enzyme activities were quenched by adding 5 ml of 10% TFA.
The acetylation reaction products were quantified with RP-HPLC
as described previously.11 All peptides were custom-made (Bio-
genes) to a purity of 80%–95%. All peptides (24-mers) used
as substrates contain seven unique N-terminal amino acids
because these are the major determinants influencing N-terminal
acetylation. The next 17 amino acids are essentially identical
to the ACTH peptide sequence (RWGRPVGRRRRPVRVYP);
however, lysines were replaced by arginines so that any potential
interference by N3-acetylation would be minimized. The
following oligopeptides were used, and proteins from which
the seven N-terminal amino acids are derived are indicated:
[H]AVFADLDRWGRPVGRRRRPVRVYP[OH], RNaseP protein p30
(P78346); [H]SESSSKSRWGRPVGRRRRPVRVYP[OH], high-mobility
group protein A1 (P17096); [H]DDDIAALRWGRPVGRRRRPVRVYP
[OH], b-actin (NP 001092); and [H]EEEIAALRWGRPVGRRRRPVRVYP
[OH], g-actin (NP 001092).
Clinical Reports
Family 1
Individual II-1 was born at 371/2 weeks of gestation to a healthy
19-year-old G1P0/1. There had been concern for placental insuffi-
ciency. His birth weight was 2140 g (3rd10th centile), and his
length was 47 cm, (25th50th centile); his orbitofrontal circumfer-
ence (OFC) was 32 cm, (10th25th centile), and his Apgar scores
were 11 and 1.5 His perinatal course had been complicated by
meconium aspiration leading to central depression. A number of
distinctive features were noted at birth: large anterior and poste-
rior fontanels, prominent eyes, large ears, flared nares, a narrow
palate, a short neck, right cryptorchidism, fifth finger clinodactyly,
relatively large great toes, metatarsus valgus, and very little subcu-
taneous fat.
At 6 months of age, his weight was 4.34 kg, (<< 5th centile), and
his OFC was 39 cm, (<< 5th centile). He had severe global delays
and had only achieved a social smile as a developmental mile-
stone. His clinical course had been complicated by frequent apneic
episodes, poor feeding, and eczema. Diagnostic studies had
included karyotype analysis (46,XY), TORCH titers (which were
normal), a computed tomography (CT) scan of the head demon-
strating cerebral atrophy with enlarged ventricles and echocardi-
ography suggesting peripheral pulmonary stenosis and possibly
a septal defect.
At 111/2 months old, he presented after 2–3 weeks of emesis and
diarrhea. Upon admission he was noted to have an electrolyte
imbalance, arrhythmias (premature ventricular complexes
[PVCs], premature atrial contractions [PACs], supraventricular
tachycardia [SVT], and ventricular tachycardia [Vtach]), and cardi-
omegaly, and went into cardiopulmonary arrest from which he
could not be resuscitated. It should be noted that dysrhythmias
occurred after the electrolyte imbalance had been corrected.
Individual II-6 was born at 381 weeks of gestation to a healthy
27-year-old G6P5/6. There had been concern for placental insuffi-
ciency, and his birth weight was 3065 g, (50th centile); his length
was 47 cm, (25th50th centile), and his OFC was 33.75 cm, (50th
centile). His Apgar scores were 41 and 6.5 His perinatal course
was complicated by respiratory distress and recognition of
multiple minor anomalies: large anterior and posterior fontanels,
prominent eyes, large ears, flared nares, a short neck, hypotonia,
neurologic depression, and very little subcutaneous fat. Echocardi-
ography was performed because of a murmur, which demon-
strated persistence of the ductus arteriosus.
At 9 months of age, his weight was 6.38 kg, (<5th centile), his
length was 68 cm, (5th centile), and his OFC was at 44.2 cm,The(10th25th centile). He had moderate to severe global develop-
mental delays, achieving only a social smile and the ability to
raise his head and roll over. He was described as being very
fussy and irritable. His clinical course had been complicated by
being a poor feeder, experiencing frequent otitis media, iron
deficiency anemia, and mild eczema. His physical examination
was notable because the anterior fontanel was open and he had
down-slantingpalpebral fissures; prominenteyes; long lashes; large
ears (75th97th centile); flarednares; a short columella; a short phil-
trumwith anoverhangingupper lip; a thinvermillionborderof the
lips; anarrowpalate;microretrognathia; anumbilicalhernia; small,
‘‘high riding’’ testes; long fingers; fullness to the dorsumof the feet;
metatarsus valgus; capillary malformation over the glabella,
eyelids, philtrum, and nape of neck; and hypertonia.
Diagnostic studies had included karyotype analysis (46, XY),
very long-chain fatty acids (normal), glycerine kinase (normal),
total carnitine (slightly elevated), urine organic acids (normal), bi-
otinidase activity (normal), an EKG that was somewhat irregular,
and a CT scan of the head demonstrating cerebral atrophy versus
dysgenesis. At 91/2 months of age, he died after presenting to the
hospital with multiple apneic episodes.
Individual III-7 was born at 33 weeks of gestation to a 21-year-
old G1P0/1, reported as having gestational diabetes; he was deliv-
ered by elective C-section because of concern that he suffered from
polycystic kidneys, oligohydramnios, and pulmonary hypoplasia.
His birth weight was 1559 g, (10th25th centile), and he had
a length of 39 cm, (10th centile); his OFC was 27 cm, (3th10th
centile), and his Apgar scores were 41 and 8.5 He was noted to
have distinctive facial features and a large anterior fontanel and
right-sided cryptorchidism and inguinal hernia. His newborn
course was complicated by polycythemia, jaundice, low cortisol,
and mild pulmonary hypoplasia. He spent approximately 5 weeks
in the neonatal intensive care unit (NICU); he required assisted
ventilation for 3 days with the rest of the time dedicated to feeding
and growing. Diagnostic studies conducted during the neonatal
period included renal ultrasonography (which was normal) and
echocardiography, demonstrating a small persistent ductus arte-
riosus, a mildly decreased left ventricular systolic function, an
abnormal appearing aortic valve, and an enlargement of the right
ventricle, decreased right ventricular systolic function, and persis-
tence of the foramen ovale.
At 51/2 months of age, he was in his usual state of health until
2 days prior to admission, when he developed rhinorrhea; one
day prior to admission he developed a fever. He presented to the
hospital with increased irritability. At first he did not appear very
ill, but he quickly progressed to shock and death.
At the autopsy he was noted to have a congenital hypotonia-
lymphedema sequence; hypertelorism; a high, broad forehead
with a frontal furrow; micrognathia; cardiomegaly (the right half
of the heart was greater than left) and the persistence of the
foramen ovale; adrenomegaly; and bilateral enlarged kidneys;
and abnormal development, including fetal lobulations, glomeru-
locystic change, sclerotic glomeruli, micronodular distal tubule
proliferation, hypoplastic or small testes, a right-sided inguinal
hernia, and right-sided cryptorchidism.
Individual III-4 (Figures 1 and 2B) was born at 373 weeks of
gestation to a 28-year-old G4P3/4, reported as having gestational
diabetes. She had experienced preterm labor at 35 weeks; there
had been decreased fetal movements, and concern for intrauterine
growth retardation. His birth weight was 2410 g, (10th25th cen-
tile), and he had a length of 44 cm (<10th centile), an OFC of
32 cm (10th25th centile), and Apgar scores of 6,1 7,5 and 9.10American Journal of Human Genetics 89, 28–43, July 15, 2011 31
Figure 1. Triptych of Individual III-4
from Family 1
These pictures demonstrate the promi-
nence of eyes, down-slanted palpebral
fissures, thickened lids, large ears, flared
nares, hypoplastic alae, short columella,
protruding upper lip, and microretrogna-
thia.He was noted to have large anterior fontanels, prominent eyes,
large ears, flared nares, a short neck, and very little subcutaneous
fat. His newborn course had been complicated by hyperbilirubine-
mia, thrombocytopenia, and polycythemia.
At 31/2 months of age his weight was 3.18 kg (<5
th centile), and
he had a length of 48 cm (<5th centile), and an OFC of 35 cm (2nd
centile). He was able to smile. His clinical course was complicated
by feeding difficulties and growth failure, but he had had no
significant illness. He was noted to have a number of distinctive
features, including prominent eyes, downslanted palpebral
fissures, ocular hypertelorism, prominence of the cheeks, rela-
tively large ears, a short nose, a longer philtrum, a narrow palate,
microretrognathia, hypotonia, redundancy of the nuchal skin,
skin laxity, and little subcutaneous fat.
At 15 months of age, his weight was 9.06 kg (<3rd centile), and
he had a length of 78 cm (25th50th centile) and an OFC of 43 cm
(<3rd centile). He was able to smile. His clinical course had been
complicated by severe scoliosis leading to restrictive lung disease,
dysphagia, and eczema. He was unable to sit up, and he could not
take food by mouth. He had been hospitalized on four separate
occasions for apnea, a viral respiratory tract infection, an aspira-
tion pneumonia, and a complication of surgery infection. He
was noted to have a number of distinctive features including an
anterior fontanel closed with fibrous tissue, a palpable metopic
ridge, relative ocular hypertelorism (75th centile), deep-set eyes,
downslanting palpebral fissures, long eyelashes, a bifid and
depressed nasal tip, prominent nares, prominent ears, a short
neck with excess nuchal skin, torticollis, pectus excavatum, scoli-
osis, and a small scrotal sack with left cryptorchidism. He had been
able to build up subcutaneous fat stores, presumably because of G
tube feeding,. He developed a very thick, dark head of hair by his
first birthday.
Diagnostic studies had included urine organic acids (normal);
serum immunoglobulins (normal); comparative genomic hybrid-
ization U-array 44 k platform (normal); and an MRI of the brain
with spectroscopy that demonstrated bilateral symmetric globus
pallidus T2 prolongation without diffusion restriction, a nonspe-
cific elevation of choline and prominence of the Sylvian fissures,
immature myelination of the splenium, and moderate lateral
and third ventricular dilation without identified cause. An MRI
of the spine demonstrated convex-right curvature reflecting
compensation for moderately severe convex right C-shaped
thoracic neuromuscular scoliosis without any noted congenital
vertebral segmentation anomalies.32 The American Journal of Human Genetics 89, 28–43, July 15, 2011He had renal ultrasonography (normal),
and echocardiography demonstrated a
small perimembranous ventricular septal
defect (VSD), patent foramen ovale or
small secundum atrial septal defect,
a mild left atrial enlargement, a trivial
pulmonary stenosis, and a trivial bilateral
branch pulmonary artery stenosis. Cranialradiography demonstrated a small sella turcica. Holter monitoring
and the EKG had been entirely normal, but he eventually devel-
oped a nonspecific T-wave abnormality.
He died at 15 months of age after a protracted hospitalization
during which he originally presented with multiple hypoxic epi-
sodes.Hehad a surgical correctionof his severe scoliosis to optimize
his pulmonary function. He developed a bradyarrhythmia and
hypoxia and eventual pulseless electrical activity. After then suffer-
ing a full arrest and resuscitation, he was supported by mechanical
ventilation until his parents chose to withdraw support.
An extensive autopsy of individual III-4 revealedmultipleminor
external anomalies, severe scoliosis, an enlarged heart with a form
fruste of a perimembranous VSD, and several findings that could
be attributed to hypoxia and ischemia during individual III-4’s
terminal course, including slight waviness of myocardial fibers
(early ischemic change), pulmonary congestion and intra-alveolar
edema, serous effusions in all body cavities, mid- to central zone
hepatocytic necrosis, and acute neuronal ischemia in the brain.
Focal segmental and global glomerulosclerosis in the outer renal
cortex suggested a more chronic or remote injury that might or
might not be related to the underlying genetic disorder, but no
other histologic or ultrastructural lesion was identified.
Individual III-6 was recently born at 354 weeks of gestation to
a 28-year-old G2P1/2, reported as having gestational diabetes.
His birth weight was 2604 g, (50th75th centile), and he had
a length of 48 cm, (75th centile), an OFC of 32.5 cm, (50th75th
centile), and an Apgar scores of 41 and 9.5 He was admitted directly
to the NICU because of respiratory distress and remained there
because of feeding difficulties and mild hyperbilirubinemia. He
was noted to have a number of distinctive features including a rela-
tively large anterior fontanel, prominent eyes, downslanted palpe-
bral fissures, ocular hypertelorism, prominent cheeks, relatively
large ears, a short nose, a longer philtrum, a narrow palate, micro-
retrognathia, left cryptorchidism, a left inguinal hernia and a large
right hydrocele, skin laxity, little subcutaneous fat, broad great
toes, and hypotonia. Echocardiography demonstrated a thickened
bicuspid aortic valve and mild pulmonary hypertension. A CT
scan of the head was remarkable only for a cephalohematoma.
His clinical course has been complicated thus far by continued
feeding difficulties and growth failure.
Family 2
Family 2 presented originally in 1977 when individual II-1
(Figure 2D) was born at 43 weeks of gestation to his 25-year-old
primigravid mother by Cesarean section because of cephalopelvic
Figure 2. Pedigree Drawing and Pictures of Families 1 and 2
(A) Pedigree drawing for family 1. The most recent deceased individual, III-4, is the most well-studied subject in the family and is indi-
cated by an arrow. Genotypes are marked for those in which DNA was available and tested. The following abbreviations are used: SB,
stillborn; þ, normal variant; mt, rare mutant variant.
(B) Pictures of four affected and deceased boys in this family, showing the aged appearance.
(C) Sanger sequencing results of NAA10 in individual III-4 from family 1.
(D) Pedigree for family 2. Individual III-2 is the most well-studied subject in the family and is indicated by an arrow.
(E) Picture of individuals II-I and III-2 in family 2 at ~1 year of age.disproportion. He weighed 3.3 kg (25th50th centile), measured
51 cm in length (50th75th centile), and had a head circumference
of 32 cm (<5th centile); he was assigned Apgar scores of 61 and 8.5
His testicles were undescended. He had poor feeding, jaundice
with a peak bilirubin of 15 mg/dl, and vasomotor instability. He
was transferred to a tertiary hospital at 8 days of age. At 7 months
of age, he weighed 7.33 kg, measured 59 cm, and had a head
circumference of 40.75 cm (all<5th centile). His ears and palpebral
fissures were large for his chronological age, and he appeared to
have bilateral ptosis. His had coarse facial features, horizontal
wrinkles on his forehead, lax skin with irregular fat deposits
beneath, and increased facial and body hair. His phallus was large
at 4 cm, and his testes had descended. A skeletal survey showed de-
layed osseous development. His psychomotor development was
delayed. A diagnosis of Donohue syndrome (MIM 246200) was
suggested. At 8 months of age, he was admitted for traction of
a congenitally dislocated left hip. Traction was insufficient to
reduce the dislocation so a closed reduction under anesthesiaThewas performed, and he was placed in a half-body cast. On the
evening after the procedure, he apparently aspirated and had
a respiratory arrest, and then had generalized seizures and an
apparent posthypoxia encephalopathy. He recovered from this
and was discharged but died at home several days later.
In 2005, individual III-2 (Figure 2D) was born at 39.7 weeks of
gestation to a 25 year-old primigravida. The pregnancy was
complicated by fetal supraventricular tachycardia, which occurred
at 20 weeks of gestation and was controlled with maternal admin-
istration of flecainide. At birth he weighed 2.66 kg (5th centile),
measured 46 cm (5th10th centile), had a head circumference of
32 cm (5th10th centile), and was assigned Apgar scores of 71
and 9.5 He had infraorbital creases, a horizontal crease across his
chin, and prominent nasolabial folds. He had a glabellar vascular
stain; his forehead was wrinkled, giving him a worried look, and
he appeared aged. He had prominent areolae and nipples, which
were normally spaced, but no palpable breast tissue. He had
a generalized increase in fine body hair. He had bilateral inguinalAmerican Journal of Human Genetics 89, 28–43, July 15, 2011 33
Table 1. Features of the Syndrome in Family 1
Category Features
Growth postnatal growth failure
Development global, severe delays
Facial wrinkled foreheads; prominence of eyes,
down-sloping palpebral fissures, thickened lids;
large ears; flared nares, hypoplastic alae, short
columella; protruding upper lip; microretrognathia
Skeletal delayed closure of fontanels;
broad great toes
Integument redundancy/laxity of skin, minimal subcutaneous
fat, cutaneous capillary malformations, very fine
hair and eyebrows
Cardiaca structural anomalies (ventricular septal defect,
atrial level defect, pulmonary artery stenoses),
arrhythmias (Torsade de points, PVCs, PACs,
SVtach, Vtach), death usually associated with
cardiogenic shock preceded by arrhythmia.
Genitala inguinal hernia, hypo- or cryptorchidism
Neurologica hypotonia progressing to hypertonia, cerebral atrophy
neurogenic scoliosis
a Features of the syndrome demonstrating more variability. Though variable
findings of the cardiac, genital and neurologic systems were observed, all
affected individuals manifested some pathologic finding of each.hernias. The first and second toes appeared widely spaced. His
karyotype was normal (500 bands). His copper and ceruloplasmin
levels were low, but his plasma catecholamine levels were normal,
ruling out Menkes syndrome (MIM 309400). His carbohydrate-
deficient transferrin levels were normal. An echocardiogram re-
vealed no structural or functional abnormalities. Inguinal hernior-
rhaphywas performed uneventfully at 6 weeks of age. At 5months
of age, he weighed 4.35 kg, measured 56.2 cm, and had a head
circumference of 39 cm (all <5th centile). Despite hypertonia
and hyperreflexia, his development was proceeding normally. He
had eczema that was responding to topical corticosteroids. At
7.5 months, he weighed 5 kg, measured 61.3 cm and had a head
circumference of 40 cm (all <5th centile), and his weight-for-
length was 5%. He had little subcutaneous fat, which gave him
a wizened look. His ears measured 4.6 cm (50th centile), appeared
large for the size of his body, and had fleshy lobules. His philtrum
measured 1.5 cm and appeared long and prominent. He was
socially engaging, vocalized mostly with vowels, and could roll
over, but could not sit independently. Subtelomeric fluorescence
in situ hybridization analysis was normal. Eye evaluation showed
only mild lagophthalmos. By 11 months of age, two incisors had
erupted; a pincer grasp was emerging, and he could maintain
a sitting position if placed into one. He vocalized with screeching
and squealing but did not babble. At 11.5 months of age, he pre-
sented with symptoms of acute gastroenteritis and was admitted
for rehydration. Clostridium difficile toxin testing was positive.
He experienced three tonic-clonic seizures, and there was decere-
brate posturing during the last. After loading with phenobarbital
was performed, no further seizures occurred, and he returned to
baseline. He continued to have excessive stool output, but electro-
lyte levels remained normal. He experienced increased difficulty in
breathing and poor perfusion and was transferred to the prenatal
intensive care unit, where he had a wide complex rhythm at
120–140 beats per minute. Ultimately, the rhythm became irreg-
ular, pulses were not palpable, and attempts to resuscitate him
were unsuccessful. The autopsy showed severe micro- and macro-
vesicular steatosis. Because of the prenatal SVT and the rhythm
disturbance without any causal electrolyte disturbance at the
end of his life, his heart was evaluated postmortem for abnormal-
ities of the conduction system. This analysis showed focal suben-
docardial scarring, but no cardiomyopathy or conduction system
abnormalities were found. Rare inflammatory infiltrates suggested
the possibility of a resolved infection.
In 2007, individual III-4 (Figure 2D) was born at 34 weeks of
gestation to his 24-year-old mother, who had a 3-year-old
daughter at the time. At 6.5 months of age, he had an episode of
aspiration, after which gastrostomy and a tracheostomytubes
were placed. At the age of 15 months, he was hospitalized for
5 weeks for an infection. The family was told a defibrillator was
needed and surgery was done for this. Two days after his discharge,
he died at home at the age of 16 months.Table 2. Coverage Statistics in Family 1 Based on GNUMAP
Region
RefSeq
Transcripts
Unique
Exons
Percent Exon
CoverageR 13
X chromosomea 1959 7486 97.8
chrX:10054434–40666673 262 1259 98.1
chrX:138927365–153331900 263 860 97.1
a On the X chromosome, there are 8222 unique RefSeq exons. Of these exons, 73
were designated as pseudoautosomal or repetitive sequences (UCSC Genome Br
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Family 1
Individuals II-1 and II-6 from family 1 (Figure 1 and
Figure 2) presented in the mid-1980s to the University of
Utah Medical Center. These boys had striking similarity to
each other with an array of sharedmanifestations (Table 1).
Both subsequently died in infancy. At that time no specific
diagnosis could be made, and the inheritance pattern was
uncertain, though autosomal-recessive and X-linked
inheritance modes were considered. X-linked inheritance
was confirmed in the next generation, when individuals
III-4 (Figure 1) and III-7 (Figure 2A) presented. The aged
appearance was the most striking part of the disease.Family 1 X-Chromosome Exon Capture
and Sequencing
Two genomic microarray analyses in individual III-4 did
not show any likely causal copy-number variants. Accord-
ingly, X chromosome exon capture and sequencing were
used to screen for variants within coding regions. WePercent Exon
Coverage R 103
Unique
Genes
Average Base
Coverage
VAAST
Candidate SNVs
95.6 913 214.6 1 (NAA10)
95.9 134 213.5 0
94.9 132 177.1 1 (NAA10)
6 were excluded from the SureSelect X-Chromosome Capture Kit because they
owser).
Table 3. The SNV Count, Nonsynonymous Coding SNV Count, and
Ti/Tv Ratio for Each Individual for Each Variant Analysis Pipeline in
Family 1
Sample Pipeline SNV Count Nonsynonymous Ti/Tv
III-4 samtools 1499 114 2.0
GATK 1546 þ 236a 146 þ 6
(nonsynonymous þ
frame)
2.0
GNUMAP 2168 155 2.0
II-2 samtools 2512 219 1.6
GATK 1999 þ 270a 168 þ 8 2.1
GNUMAP 2893 183 2.0
III-2 samtools 1491 106 2.0
GATK 1509 þ 252a 134 þ 10 2.0
GNUMAP 2062 131 2.0
I-2 samtools 2637 229 1.5
GATK 2032 þ 278a 160 þ 10 2.0
GNUMAP 2920 183 1.9
II-8 samtools 1513 108 1.9
GATK 1572 þ 243a 136 þ 8 1.9
GNUMAP 1924 139 2.0
a Microindels ascertained with GATK pipeline.
Table 4. Summary of the Filtering Procedure and Candidate
Genes with VAAST
SNV-Calling Pipeline GATK Samtools GNUMAP
III-4 (total SNVs) 1546 1499 2168
III-4 (nsSNVs) 146 114 155
VAAST candidate genes
(NAA10 ranking)
4 (3) 3 (2) 5 (2)
Present in III-4 and mother II-2
(nsSNVs)
122 107 116
VAAST candidate genes
(NAA10 ranking)
3 (2) 2 (1) 2 (2)
Present in III-4, mother II-2,
and grandmother I-2 (nsSNVs)
115 95 104
VAAST candidate genes
(NAA10 ranking)
2 (1) 2 (1) 1 (1)
Present in III-4, II-2, and I-2,
absent in brother III-2 and
uncle II-8 (nsSNVs)
8 6 8
VAAST candidate genes
(NAA10 ranking)
1 (1) 1 (1) 2 (1)established the following filtering criteria for five samples
to determine the final set of variant calls: variants must
be present on the X chromosome in individual III-4 (hemi-
zygous), heterozygous in individual II-2 (the mother),
heterozygous in individual I-2 (the grandmother), and
absent in individuals III-2 and II-8 (the unaffected
brother and unaffected uncle). Table 2 shows the coverage
statistics of the X chromosome exon capture. The exon
sequencing reads were processed by three independent
variant-calling pipelines to increase the accuracy for
SNVs and/or microindels (Table 3). These three variant-
calling pipelines converged on a small list of candidate
variants, which were annotated by ANNOVAR16 for func-
tional importance. One mutation had not been seen
previously in dbSNP or the 1000 Genomes Project data-
base. It is missense mutation c.109T>C in NAA10, which
predicts p.Ser37Pro (MIM 300013) and was confirmed by
Sanger sequencing (Figure 2C). We confirmed that this
mutation was not present in 401 participants (90% white
and mixed European descent and 96% nonlatino) in the
ClinSeq project22 nor was it seen in a combination of
~6000 genomes or exomes (the majority of white and
mixed European descent) collected in ongoing projects at
Children’s Hospital of Philadelpha, University of Utah,
and/or BGI.
VAAST Analysis
We also used a recently developed tool (VAAST),23 which
identifies disease-causing variants, to analyze the exonThecapture data from family 1. VAAST annotates the SNVs
on the basis of their effect on coding sequences, selects
the variants compatible with the pedigree, and performs
a statistical analysis on the X chromosome genes to iden-
tify the variant(s) most likely to be disease-causing. In
the candidate-gene identification step, VAAST uses a likeli-
hood ratio test that incorporates both amino acid substitu-
tion frequencies and allele frequencies to prioritize candi-
date genes on the basis of SNVs present in those genes.
The analyses by VAAST of the variant sets generated from
the three variant-calling pipelines yielded similar results
and identified the same causal mutation in NAA10. With
SNVs from the affected child (individual III-4) alone,
VAAST was able to narrow the candidate-gene list to fewer
than five genes (Table 4). We then filtered the data by only
selecting SNVs shared by the mother (individual II-2) and
the affected child (individual III-4). This subset resulted
in three, two, and two candidate genes in the GATK, Sam-
tools, and GNUMAP datasets, respectively (Table 4). Next,
we filtered the data by selecting SNVs shared by themother
(individual II-2), the maternal grandmother (individual
I-2), and the affected child (individual III-4). This subset re-
sulted in two, two, and one hits in the three datasets,
respectively, and NAA10 ranked first in all three lists.
When we further excluded the SNVs that were present in
the unaffected brother and uncle, VAAST identified a single
candidate disease-causing variant in NAA10 in the GATK
and the Samtools datasets and two candidate disease-
causing variants in NAA10 and RENBP in the GNUMAP
dataset (Table 4).
Confirmation in Other Family Members
DNA samples from other members of family 1 were
obtained from the medical examiner; the samples includeAmerican Journal of Human Genetics 89, 28–43, July 15, 2011 35
Table 5. Haplotype Analysis in Affected Males from Family 1: FineMapChX_STR Results
Sample Allele Markera hg18 Position Chromosome
III-4 219 DXS1275 (AFM261ZH5) 68,431,124 Xq13.1
III-6 225
II-6 (FFPE tissue) ?
III-7 (FFPE tissue) 225
III-4 253 DXS8037 (AFMA285XG5) 74,040,314 Xq13.3
III-6 257
II-6 (FFPE tissue) 242
III-7 (FFPE tissue) 257
III-4 162 DXS986 (AFM116XG1) 79,267,784 Xq21.1
III-6 164
II-6 (FFPE tissue) 168
III-7 (FFPE tissue) 164
III-4 106 DXS8076 (AFMB357XE5) 82,666,040 Xq21.1
III-6 98
II-6 (FFPE tissue) 98
III-7 (FFPE tissue) 98
III-4 217 DXS1203 (AFM262VG1) 92,654,766 Xq21.32
III-6 217
II-6 (FFPE tissue) 217
III-7 (FFPE tissue) 217
III-4 131 DXS990 (AFM136YC7) 92,887,320 Xq21.32
III-6 127
II-6 (FFPE tissue) 127
III-7 (FFPE tissue) 127
III-4 253 DXS6799 (GATA29G07) 97,265,664 Xq21.33
III-6 257
II-6 (FFPE tissue) 257
III-7 (FFPE tissue) 257
III-4 201 DXS8020 (AFMA162TC1) 99,455,440 Xq22.1
III-6 212
II-6 (FFPE tissue) 203
III-7 (FFPE tissue) 212
III-4 128 DXS1106 (AFM263WE1) 102,618,641 Xq22.2
III-6 130
II-6 (FFPE tissue) 126
III-7 (FFPE tissue) 130
III-4 317 DXS8055 (AFMB291YE5) 114,561,258 Xq23
III-6 315
II-6 (FFPE tissue) 317
III-7 (FFPE tissue) 315
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Table 5. Continued
Sample Allele Markera hg18 Position Chromosome
III-4 206 DXS1001 (AFM248WE5) 119,720,593 Xq24
III-6 199
II-6 (FFPE tissue) 206
III-7 (FFPE tissue) 199
III-4 165 DXS1047 (AFM150XF10) 128,902,983 Xq25
III-6 165
II-6 (FFPE tissue) 165
III-7 (FFPE tissue) 160
III-4 90 DXS1227 (AFM317YE9) 140,630,173 Xq27.2
III-6 82
II-6 (FFPE tissue) 90
III-7 (FFPE tissue) 82
III-4 170 DXS8043 (AFMB018WD9) 143,836,276 Xq27.3
III-6 156
II-6 (FFPE tissue) 170
III-7 (FFPE tissue) 170
III-4 83 DXS8091 (AFM345WG9) 147,410,588 Xq28
III-6 83
II-6 (FFPE tissue) 83
III-7 (FFPE tissue) 83
c.109T>C in NAA10 ~152,850,921b Xq28
III-4 310 DXS1073 (AFM276XH9) 153,482,054 Xq28
III-6 310
II-6 (FFPE tissue) 310
III-7 (FFPE tissue) 310
a Genomic position represents a single nucleotide within the STR.
b Maximum Shared Region (hg18): chrX:143,836,276–154,913,754 (telomere) (11 Mb).DNA isolated from FFPE tissues from two of the deceased
boys. Sanger sequencing in 14 DNA samples derived
from blood or FFPE tissue from the family confirmed that
the mutation in NAA10 cosegregated according to the
deduced affection status or carrier status in all members
of the family (Figure 2A and Figures S1–S5, available
online). During the course of this work, another boy
(individual III-6) was born to individual II-3 in family 1
(Figure S6). This boy was clinically diagnosed as having
the syndrome and also was confirmed to have the muta-
tion by Sanger sequencing.
Haplotype Analysis
Having identified a putative causative mutation from the
X chromosome exon analysis, we performed haplotype
analysis on family1 toexclude regionsof theXchromosome
from which we could have possibly missed a mutation
because of a lack of exon capture or a lack of sequencingThecoverage. We performed haplotype analysis by using two
data sets: (1) the SNVs derived from X chromosome exon
sequencing of individual III-4 and (2) STR genotyping of
individual III-4, two other affected males (individuals II-6
and III-7) in the family, and carrier females I-2, II-2, and
II-5. Haplotype analysis narrowed the possible candidate
regions to X chromosome positions 10,054,434–
40,666,673 (~30 Mb) and 138,927,365–153,331,900
(~14 Mb) (Table 5 and Table S1). The sequencing data
showed that of the ~155 Mb on the X chromosome, the
affected brother (III-4) and unaffected brother (III-2) were
identical at ~71% and were recombinant at only 29%. The
~14 Mb region is located on the telomeric end of the long
armof theX chromosome and includesNAA10. Subsequent
addition of STR genotyping from thenewborn affectedmale
(III-6) further narrowed this interval to chrX:143,836,276–
154,913,754 (telomere) (~11 Mb), which still includes
NAA10 (Table 5).American Journal of Human Genetics 89, 28–43, July 15, 2011 37
Coverage Analysis
Exon capture techniques cannot capture all exonic regions
because of design issues with replicative regions; this can
therefore result in an incomplete set of variants. The X
chromosome Agilent design consists of over 3 Mb of
exon intervals. We evaluated the capture and sequencing
coverage for all the currently known 1959 chrX transcripts
in RefSeq (hg18). On the X chromosome, there are 8222
unique RefSeq exons. Of these exons, 736 were excluded
from the SureSelect X-Chromosome Capture Kit because
they were designated as pseudoautosomal or repetitive
sequences (UCSC Genome Browser). The remaining 7486
exons have an average length of 358.9 bases and are
covered on average by 5.7 bait probes per exon (bait probes
were 120 bases long). The average read coverage in these
regions was 214.6 reads per base; in these regions an
average of 97.8% of the bases were covered by one or
more reads, and 95.6% were covered at 103 or better.
We also analyzed the average coverage for each gene
(calculated as the total read bases within exons divided
by the exon length) more specifically in the affected haplo-
type in the 14 Mb critical region derived from analysis of
family 1 (Table S2). The average coverage was 1853 among
the 167 nonpseudoautosomal or duplicative RefSeq tran-
scripts (110 unique genes) in the 14 Mb region. These
167 transcripts consist of 864 exons, of which 860 had
some read coverage and 809 had reads covering more
than 95% of the bases in the exon. Most of the exon
portions in the 14 Mb region that were not covered by
reads were from the 89 exons not included in the SureSe-
lect X-Chromosome Capture Kit because they were in the
pseudoautosomal or duplicative regions. There was some
coverage on a handful of these exons as well as intronic
and intergenic regions flanking covered exons as a conse-
quence of the experimental protocol. For example, if an
excluded exon or intronic sequence is close (~500 bases)
to an exon that is captured, the long fragment size (and
the fact that we only sequence the end of the fragment)
can lead to reads for the exon or intron. In the NAA10
haplotype region, we had greater than 103 coverage for
86% of the exons in the region for family 1; the corollary
of this means that 97 exons do not have 103 coverage in
the NAA10 region. However, of the 856 exons in the 14
Mb region that did have >103 coverage, the GNUMAP
and VAAST approach found only two candidate SNVs
that met our criteria (present in proband, not present in
his brother and uncle, polymorphic in his mother and
grandmother, nonsynonymous, not in the 1000 genomes
or dbSNP), and in the exons in the 30 Mb region, no SNVs
met our criteria. Theoretically, we could have nonetheless
missed a crucially important variant, so we needed to use
parallel approaches to prove causality of the variant in
NAA10.
A Second Family
During preparation of a manuscript reporting the above
results, another group (L.M.B., J.J.J, L.G.B.) communicated38 The American Journal of Human Genetics 89, 28–43, July 15, 2011to us that they had also identified the NAA10 c.109T>C
mutation in an apparently unrelated family (herein desig-
nated as family 2) with an indistinguishable phenotype
(see Figure 2D and 2E). Haplotype analysis had been per-
formed for family 2, and it identified a shared region
of chrX:140,061,918–154,913,754 (~14 Mb) in three
carrier females (I-2, II-2, and II-3) that was not present
in an unaffected male (III-5). The borders of the region
were defined by recombinant marker GATA31E08 and
the q terminus.
Massively parallel sequencing of X chromosome exons
was done on DNA samples from an obligate carrier and
her unaffected child as previously described.9 The entire
X chromosome exon region target sequence was
2,784,426 bp, and theX chromosome exon region oligonu-
cleotide library was designed to target 2,264,175 bp of this
(81.3%). The target-selected DNA libraries from one female
heterozygote (M87_4) and one unaffected male child
(M87_5) were sequenced on one lane each of an Illumina
GAIIx in paired-end 75 bp configuration, which yielded,
respectively, 75,382,114 and 65,015,016 reads (separate
results are given for each sample) or 5,729,040,664 and
4,941,141,216 bp of total sequence. Of the filtered aligning
sequence, 20.9% and 11.9% could be uniquely aligned to
the entire X chromosome exon region target (2,784,426
bases). This aligned sequence yielded a gross overall
coverage of 20583 and 17753 of the entire X chromosome
exon region target. The capture efficiency varied across the
targets; 2,538,791 and 2,464,367 bp (89.8%) of the entire
X chromosome exon region yielded R13 coverage,
2,305,571 and 2,251,868 bp (81.8%) yielded R103
coverage, and 2,254,446 and 2,183,075 bp (79.7%) yielded
R203 coverage. The Most Probable Genotype (MPG)
variant-calling software24 was able to make base calls on
2,295,223 and 2,378,985 bp of this sequence (82.4% and
85.4%).
The genotypes were filtered on the basis of several attri-
butes that were felt to be appropriate for this disorder
(Table 6). Heterozygosity was used because the test subject
was an unaffected female carrier for an X-linked trait. We
performed further filtering to include nonsynonymous,
splice-site, frame-shifting, and nonsense variants. Filtering
to exclude variants present in dbSNP or in the ClinSeq
cohort (401 control individuals)22 was also performed.
Finally, a filter that bounded the variants genomically
within the shared 14 Mb haplotype region was applied.
This left one variant, a single missense mutation,
c.109T>C in NAA10. This variant was confirmed in the
other individuals, and mutation status segregated with
affection status and carrier status (Figure 2D).
Genome-wide Significance
We next assessed whether adding members of family 2
would improve the power of the VAAST analysis. We
combined variants from individual III-4 in family 1 with
the obligate carrier mother (II-2) in family 2 and performed
VAASTanalysis on the 216 coding SNVs present in either of
Table 6. Filtering Analysis of Family 2
X chromosome
exons
Exons in
Shared Haplotype
Total SNVs 3441 585
Heterozygous 2381 418
Stop/NonSyn/FS/Splicea 136 35
Not in dbSNP 40 10
Not in ClinSeq 20 1 (NAA10)
a The following abbreviations are used: Stop, nonsense variants; NonSyn, non-
synonymous variants; FS, frame-shifting variants; Splice, splice-site variants.the two individuals. After incorporating the mother from
family 2, NAA10 was the only candidate gene, and the
result was statistically significant (p value ¼ 3.8 3 105;
Bonferroni corrected p value ¼ 3.83 105 3 729 ¼ 0.028).Lack of Relatedness of the Two Families
Both families are of mixed European ancestry. To evaluate
whether the two families inherited the NAA10 variant
from a recent shared founder, we examined SNVs
surrounding this variant to test for evidence of identity-
by-descent (IBD). Assuming no sequencing errors, the
largest region consistent with IBD between the two
probands is only 30 kb (Table 7). By relaxing this assump-
tion to allow for multiple sequencing errors, we find theTable 7. Relationship Inference of the Two Families
Position
First Family Secon
Inconsistent with IBD Proband Impu
152802312 X G A
152804123 X A G
152821601 X A G
152821643 X C T
152825187 X G A
152829448 X G A
152853035 G G
152860231 X T G
152932023 A A
152937386 G G
152945374 C C
153317692 X G A
153321366 G G
153534024 X C A
153534719 X C G
153556589 X A G
153557591 X G A
153557667 X T C
Thelargest region consistent with IBD is 704 kb, which is
approximately 1.5 centiMorgans (cM)25 (Figure 3). If the
two probands were as distantly related as fourth cousins,
the expected IBD segment size would be 20 cM (condi-
tioned on ascertainment from the presence of a shared
variant).26 Therefore, the variation between the two
probands in this region is inconsistent with recent shared
ancestry. If the two probands inherited the mutation from
a more distant founder and if they share the entire 700 kb
region, the estimated time to the founder would be around
3300 years ago. Because this variant is an X-linked reces-
sive lethal mutation, the probability of its being eliminated
in each transmission is 1/3, and the variant is therefore
highly unlikely to have occurred 3300 years ago. We
conclude that the disease-causing variant in the two fami-
lies resulted from two independent mutational events.
Functional Analysis
N-terminal acetylation of proteins is catalyzed by
N-terminal acetyltransferases (NATs). The primary NAT in
terms of targeted substrates is the evolutionarily conserved
NatA.27–29 The functional impact of N-terminal acetyla-
tion remains quite elusive, but recent data suggest a role
as a destabilization signal for proteins.30 The human
NatA complex is composed of the catalytic subunit
hNaa10p (hARD1) and the auxiliary subunit hNaa15p
(NATH/hNAT1), both essential for its activity.31 Increased
NatA levels have been linked to tumor progression, andd Family
ted Genotype of Proband Unaffected Son Mother
G AG
A GA
A GA
C TC
G AG
G AG
A GA
G GG
A AA
G GG
C CC
A AA
G GG
C AC
C GC
A GA
G AG
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Figure 3. IBD Analysis of the Two Fami-
lies in the Genomic Region Surrounding
c.109T>C
Informative SNVs consist of two classes:
rare SNVs present in the proband from
family 1 in genomic regions with high
coverage in the second family, and
common SNVs present in the first proband and at least one member of the second family. Variant c.109T>C is indicated by the triangle.
We imputed the genotype of the proband from family 2 from the genotypes of the mother and unaffected sibling of the second family
(see Table 7). SNVs inconsistent with IBD, in which the imputed genotype of the second proband does not match the first proband, are
indicated with an X. After allowing for multiple sequencing errors, the largest genomic segment consistent with IBD is around 700 kb in
length.depletion of NatA subunits from cancer cells induces cell-
cycle arrest and apoptosis.32 Human Naa10p is a protein
of 235 amino acid residues, of which the first 178 residues
compose a globular region, whereas the latter 57 residues
are predicted to form an unstructured and flexible
C-terminal tail.33 Thus, Ser37 is located in a structured
part of hNaa10p. For many soluble globular proteins, Pro
is known to be potentially disruptive for secondary struc-
ture elements such as the alpha-helix and beta-sheets.34
Thus, although the structure of hNaa10p is undetermined,
the p.Ser37Pro mutation could indeed affect the structure
of hNaa10p and thereby the catalytic activity. Ser37 and
its surrounding residues are highly conserved among
eukaryotes,31 suggesting an essential function. A SIFT anal-
ysis predicting whether an amino acid substitution affects
protein function35 strongly suggested that a substitution
from Ser to Pro at position 37would affect protein function
with a score of 0.00.
In order to directly assess the functional consequences of
the hNaa10p p.Ser37Pro mutation, we analyzed the wild-
type (WT) and the mutant proteins by a quantitative in vi-
tro N-terminal acetylation assay. The enzyme activities of
hNaa10p WT and hNaa10p p.Ser37Pro were determined
with four unique peptides as substrate; these peptides
having been previously shown to be acetylated by
hNaa10p and NatA (Figure 4). Compared to hNaa10p
WT, hNaa10p p.Ser37Pro displayed a 60%–80% reduction
in NAT activity toward the in vivo substrate RNaseP
protein p30 (AVFAD-) and toward b-actin (DDDIA-) and
g-actin (EEEIA-). In contrast, the activity toward the NatA
substrate high-mobility group protein A1 (SESSS-) was
only reduced by 20% (Figure 4). The oligopeptides AVFAD-
and SESSS- represent classical cotranslational NatA
substrates, being the N termini of proteins that are partially
(AVFAD-) or fully (SESSS-) acetylated by NatA in HeLa
cells.27 On the other hand, b-actin (DDDIA-) and g-actin
(EEEIA-) are nonclassical substrates recently shown to be
acetylated more efficiently by hNaa10p/NatA than the
classical substrates were, representing a posttranslational
NAT activity.36Discussion
The data presented here show that a mutation in an
enzyme involved in N-terminal acetylation of proteins40 The American Journal of Human Genetics 89, 28–43, July 15, 2011leads to a distinct, previously undescribed X-linked pheno-
type in humans and that males who carry the hypomor-
phic hNaa10p p.Ser37Pro allele die in infancy with cardiac
arrhythmias. N-terminal acetylation is one of the most
common protein modifications in humans, occurring on
approximately 80% of all human proteins27 It is catalyzed
by several distinct NATenzymes, of which the major one is
NatA.29 The catalytic subunit of the NatA complex,
hNaa10p, is essential for survival in the organisms
Drosophila melanogaster,37 Trypanosoma brucei,38 and Cae-
norhabditis elegans.39 It is presumed that an amorphic
NAA10mutation would lead to embryonal lethality in hu-
mans, although one can only prove this by analyzing
tissues from pregnancies that did not survive to term.
The strong conservation of Naa10p Ser37, the predicted
functional effect of p.Ser37Pro due to structural distortion,
and the demonstrated disruption of catalytic activity by
p.Ser37Pro (Figure 4) strongly imply that the hemizygous
males with hNaa10p p.Ser37Pro have impaired NatA func-
tion. Thus, a variety of protein N termini, both those that
are cotranslationally and those that are posttranslationally
acetylated (e.g., actins), are likely to be insufficiently acet-
ylated. Most likely, the serious consequences of the
p.Ser37Pro mutation are caused by the lack of N-terminal
acetylation for one or several proteins strictly requiring
this modification for function or for maintenance of
adequate amounts in the cell. Because hNaa10p has also
been suggested to performN-lysine (N-epsilon) acetylation
of proteins such as beta-catenin,40 a lack of N-lysine acety-
lation of selected substrates could also cause the observed
effects. Finally, proposed noncatalytic functions of
hNaa10p41,42 could be affected in the p.Ser37Pro mutant
and thereby also play a role in the observed phenotypes.
We have demonstrated herein that a probabilistic
disease-causing variant discovery algorithm can readily
identify and characterize the genetic basis of a previously
unrecognized X-linked syndrome. We have also shown
that this algorithm, when used in parallel with high-
throughput sequencing, can identify variants with high
prioritization for causing disease with as few as two indi-
viduals. In this instance, we screened ~150 variants distrib-
uted among ~2000 transcripts on the X chromosome in
one sample from individual III-4 in family 1. With no prior
filtering, we prioritized three to five possible candidate
genes, and the mutation in NAA10 ranked second overall
(Table 4). Including exon capture data from relatives
Figure 4. NAT Activity of Recombinant hNaa10p WT
or p.Ser37Pro toward Synthetic N-Terminal Peptides
(A and B) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed
with the indicated oligopeptide substrates (200 mM for SESSS and
250 mM for DDDIA) and saturated levels of acetyl-CoA (400 mM).
Aliquots were collected at indicated time points and the acetyla-
tion reactions were quantified with reverse phase HPLC peptide
separation. Error bars indicate the standard deviation based on
three independent experiments. The five first amino acids in the
peptides are indicated, for further details see Subjects and
Methods. Time-dependent acetylation reactions were performed
to determine initial velocity conditions when comparing the WT
and Ser37Pro NAT activities toward different oligopeptides.
(C) Purified MBP-hNaa10p WTor p.Ser37Pro were mixed with the
indicated oligopeptide substrates (200 mM for SESSS and AVFAD
and 250 mM for DDDIA and EEEIA) and saturated levels of
acetyl-CoA (400 mM) and incubated for 15 min (DDDIA and
EEEIA) or 20 min (SESSS and AVFAD) at 37C in acetylation buffer.
The acetylation activity was determined as above. Error bars
indicate the standard deviation based on three independent exper-
iments. Black bars indicate the acetylation capacity of the
MBP-hNaa10p WT, whereas white bars indicate the acetylation
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first
amino acids in the peptides are indicated.
Theincreased NAA10’s ranking to first overall in just one
family. Furthermore, after combining variants from the
proband in family 1 with the obligate carrier mother in
family 2, VAAST identified NAA10 as the only statistically
significant candidate.
Although we have noted that the affected infants have
an aged appearance, we have not established any direct
link with progeria or other progeroid syndromes. The
autopsies did not reveal any premature arteriosclerosis or
degeneration of vascular smooth muscle cells, as is seen
in Hutchinson-Gilford progeria syndrome (MIM
176670).43,44 Cell lines now being derived from family 1
and possibly future animal models will provide important
insights about the pathophysiology underlying this previ-
ously unrecognized syndrome.Supplemental Data
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found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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